InsidersTradesSigma
Total declarations
Company
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Schuetz Thomas J., Chairman & CEO. Officer active across 1 company, notably Compass Therapeutics, Inc.. Cumulatively, 11 disclosures have been published. Breakdown: 9 buys · 0 sell. Total volume traded: €498k. Activity tracked since 16 November 2021. The latest transaction was disclosed on 21 June 2022 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations11 total
20,000 shares@ US$2.800.016% mcap10.7% of flowCommon StockSEC:0001171843-22-004440:0
Ideal exit: 18 Mar 2023 (T+270)
20,000 shares@ US$2.340.013% mcap8.9% of flowCommon StockSEC:0001171843-22-004408:0
Ideal exit: 13 Mar 2023 (T+270)
30,000 shares@ US$2.290.020% mcap13.2% of flowCommon StockSEC:0001171843-22-004327:0
Ideal exit: 10 Mar 2023 (T+270)
30,000 shares@ US$2.830.024% mcap15.9% of flowCommon StockSEC:0001171843-22-004190:0
Ideal exit: 3 Mar 2023 (T+270)
20,000 shares@ US$3.030.017% mcap11.4% of flowCommon StockSEC:0001171843-22-004068:0
Ideal exit: 26 Feb 2023 (T+270)
20,000 shares@ US$3.040.017% mcap11.4% of flowCommon StockSEC:0001171843-22-003978:0
Ideal exit: 20 Feb 2023 (T+270)
18,355 shares@ US$2.720.014% mcap9.4% of flowCommon StockSEC:0001171843-22-003899:0
Ideal exit: 17 Feb 2023 (T+270)
20,215 shares@ US$2.470.014% mcap9.5% of flowCommon StockSEC:0001171843-22-003771:0
Ideal exit: 11 Feb 2023 (T+270)
27,836 shares@ US$1.800.014% mcap9.6% of flowCommon StockSEC:0001171843-22-003503:0
Ideal exit: 4 Feb 2023 (T+270)
600,000 shares0Common StockSEC:0000899243-21-045310:0
600,000 shares0Common StockSEC:0000899243-21-045310
11 of 11 declarations
About Schuetz Thomas J.
Thomas J. Schuetz is Chief Executive Officer of Compass Therapeutics, Inc. He leads the company with a strategic vision, focusing on innovation and growth. His leadership is essential to achieving the company's objectives and strengthening its market position.
